Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene

European Journal of Endocrinology

Volumn 159, Issue 6, 2008, Pages 767-771

  Peppa, Melpomeni ^a   Boutati, Eleni ^a   Kamakari, Smaragda ^b   Pikounis, Vasillíos ^a   Peros, George ^a   Panayiotides, Ioannis G ^a   Economopoulos, Theofanis ^a   Raptis, Sotirios A ^a,c   Hadjidakis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Biogenomica Laboratory   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CALCITONIN; CYSTEINE; GLYCINE; PENTAGASTRIN; PHENOXYBENZAMINE; PROTEIN RET; RET PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADRENAL INCIDENTALOMA; ADRENALECTOMY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DNA EXTRACTION; EXON; FEMALE; GENETIC SCREENING; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; MALE; NUCLEIC ACID BASE SUBSTITUTION; PEDIGREE ANALYSIS; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SEQUENCE ANALYSIS; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; AMINO ACID SUBSTITUTION; CASE REPORT; GENETICS; MEDULLARY CARCINOMA; MIDDLE AGED; PATHOLOGY; PEDIGREE; REVIEW; SYNDROME; THYROID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CARCINOMA, MEDULLARY; CYSTEINE; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; PHENOTYPE; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-RET; SYNDROME; THYROID NEOPLASMS; YOUNG ADULT;

EID: 58149335397     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0476     Document Type: Article

References (23)

1. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei CC, Pacini F, Fink M, Niederle BM, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN & Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. Journal of the American Medical Association 1996 276 1575-1579.
2. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ & Hofstra RM. Current concepts in RET-related genetics, signaling and therapeutics. Trends in Genetics 2006 22 627-636.
3. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE & Evans DB. RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005 15 531-544.
4. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A & Ponder BJ. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993 363 458-460.
5. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P & Wells SA Jr. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 1993 2 851-856.
6. Punales MK, Graf H, Gross JL & Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. Journal of Clinical Endocrinology and Metabolism 2003 88 2644-2649.
7. Karga HJ, Karayianni MK, Linos DA, Tseleni SC, Karaiskos KD & Papapetrou PD. Germ line mutations analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. European Journal of Endocrinology 1998 139 410-415.
8. Kaldrymides P, Mytakidis N, Anagnostopoulos T, Vassiliou M, Tertipi A, Zahariou M, Rampias T, Koutsodontis G, Konstantopoulou I, Ladopoulou A, Bei T & Yannoukakos D. A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clinical Endocrinology 2006 64 561-566.
9. Alevizaki M. Medullary thyroid carcinoma: clinical presentation and diagnosis. In Thyroid Cancer, Thessaloniki, pp 395-411. Ed. Hercules Vainas, 2006.
10. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Cheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA & Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671.
11. Pigny P, Bauters C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerckaert JP & Porchet N. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1999 84 1700-1704.
12. Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB & Cerutti JM. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 5438-5443.
13. Jindrichova S, Vcelak J, Vlcek P, Neradilova M, Nemec J & Bendlova B. Screening of six risk exons of the RET protooncogene in families with medullary thyroid carcinoma in the Czech Republic. Journal of Endocrinology 2004 183 257-265.
14. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM & Hoppner W. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Journal of Clinical Endocrinology and Metabolism 1998 83 770-774.
15. Peppa M, Boutati S, Kamakari V, Pikounis G, Peros G, Koutsodontis G, Metaxa-Mariatou V, Economopoulos T, Raptis SA & Hadjidakis D. Novel germline mutations of the MEN1 gene in Greek families with multiple endocrine neoplasia Type 1. Clinical Endocrinology 2008. In Press, DOI:10.1111/j.1365-2265.2008.03308.x
16. Bethanis S, Koutsodontis G, Palouka T, Avgoustis C, Yannoulakos D, Bei T, Papadopoulos S, Linos D & Tsagarakis S. A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones 2007 6 152-156.
17. Kamakari S, Alevizaki M, Bei T, Peppa M, Anapliotou M, Tzanela M, Kafiri G, Papadodima E, Malaktari S, Tsagarakis S, Kaldrymides P, Rampias T, Koutsodontis G, Metaxa-Mariatou B, Giantzakis C, Konstantopoulou I & Yannoukakos D. The rare mutation of RET gene G533C is found in 15 unrelated Greek families explaining the 'RET-negative' patients FMTC/ MEN2A. (Abstract). Hormones 2008 7 (Suppl 2) 70.
18. Robledo M, Gil L, Pollan M, Cebrian A, Ruiz S, Azanedo M, Benitez J, Menarguez J & Rojas JM. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Research 2003 63 1814-1817.
19. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhäusl W & Vierhapper H. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism 2005 90 6232-6236.
20. Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, Leyland J, Whittaker J, Pharoah PD & Ponder BAJ. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia. Type 2A. Cancer Research 2006 66 1177-1180.
21. Rossi S, Fugazzola L, De Pasquale L, Braidotti P, Cirello V, Beck-Peccoz P, Bosari S & Bastagli A. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocrine-Related Cancer 2005 12 281-289.
22. De Groot JW, Links TP, Plukker JT, Lips CJ & Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 2006 27 535-560.
23. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B & Dralle H. Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 2003 349 1517-1525.